Yigla Mordechai, Tov Naveh, Solomonov Anna, Rubin Ami-Hai E, Harlev Dan
Division of Pulmonary Medicine, Rambam Medical Center, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
J Asthma. 2003 Dec;40(8):865-71. doi: 10.1081/jas-120023577.
This study tested the hypothesis that asthma can promote obstructive sleep apnea (OSA) by looking at the prevalence of OSA among patients with difficult-to-control asthma receiving long-term oral corticosteroid (CS) therapy and examined some possible etiological factors. The study design was a prospective cohort study and was conducted in the pulmonary outpatient clinic of a tertiary care center in Haifa, Israel. Twenty-two consecutive patients with severe unstable asthma, 14 on continuous and 8 on bursts of oral CS, in addition to their standard therapy for a mean of 8.9 +/- 3.3 years, underwent a night polysomnography in a sleep laboratory regardless of sleep complaints. A standard questionnaire was completed upon attending the sleep laboratory. The OSA was defined as respiratory disturbance index (RDI) of > or = 5 and typical complaints. The correlation between RDI to asthma and morphometric parameters was tested. All but one patient had OSA [95.5% prevalence], with mean RDI of 17.7 +/- 2.5. The RDI values were significantly higher in the continuous CS therapy subgroup (21.4 +/- 3.4 vs. 11.1 +/- 1.6, p < 0.05]. The study group had above normal neck circumferences and body mass index. The former increased by 12.1% +/- 3.1% % to 29.8% +/- 1% during the oral CS therapy interval but had no significant effect on RDI as a covariant. This study showed an unexpectedly high prevalence of OSA among patients with unstable asthma receiving long-term chronic or frequent burst of oral CS therapy. It may be assumed that prolonged and especially continuous oral CS therapy in asthma increases airway collapsibility.
本研究通过观察接受长期口服皮质类固醇(CS)治疗的难治性哮喘患者中阻塞性睡眠呼吸暂停(OSA)的患病率,验证了哮喘可促进阻塞性睡眠呼吸暂停这一假设,并研究了一些可能的病因。研究设计为前瞻性队列研究,在以色列海法一家三级医疗中心的肺科门诊进行。22例连续的严重不稳定哮喘患者,除接受平均8.9±3.3年的标准治疗外,14例持续口服CS,8例间断口服CS,无论有无睡眠主诉,均在睡眠实验室接受夜间多导睡眠监测。进入睡眠实验室时完成一份标准问卷。OSA定义为呼吸紊乱指数(RDI)≥5且有典型主诉。测试了RDI与哮喘及形态学参数之间的相关性。除1例患者外,所有患者均患有OSA[患病率95.5%],平均RDI为17.7±2.5。连续CS治疗亚组的RDI值显著更高(21.4±3.4对11.1±1.6,p<0.05)。研究组的颈围和体重指数高于正常水平。在口服CS治疗期间,前者增加了12.1%±3.1%至29.8%±1%,但作为协变量对RDI无显著影响。本研究显示,接受长期慢性或频繁间断口服CS治疗的不稳定哮喘患者中,OSA的患病率出乎意料地高。可以推测,哮喘患者长期尤其是持续口服CS治疗会增加气道塌陷的可能性。